mass cytometry Fluidigm Q2 Revenues Grow 19 Percent The firm noted that its base product and service revenue (excluding COVID-19 testing) increased 33 percent year over year to $26.9 million. Fluidigm Inks Comarketing Pacts With Ultivue, ImaBiotech The separate comarketing agreements with Ultivue and ImaBiotech are related to Fluidigm's Imaging Mass Cytometry technology platform. Maternal Blood Proteomic, Metabolomic Changes Could Predict Onset of Labor About two to four weeks before labor starts, changes affecting the maternal metabolome, proteome, and immunome occur, a new study found. Fluidigm CEO Lays Out Plan for 'Durable' Diagnostics, Clinical Business Post-COVID Premium Fluidigm CEO Chris Linthwaite said the company aims to further penetrate the diagnostic and clinical markets with both its microfluidics and mass cytometry businesses. Fluidigm Q4 Revenues Grow 38 Percent on COVID-19-Driven Microfluidics Growth The firm also announced a COVID-19 testing deal with George Mason University and a CyTOF supply and distribution agreement with Zhejiang PuLuoTing Health Technology in China. Feb 10, 2021 ImmunoScape, Johns Hopkins Team Profiles T Cell Response in COVID-19 Patients Premium Nov 5, 2020 Fluidigm Q3 Revenues Jump 50 Percent Driven by COVID-19 Testing Aug 10, 2020 T Cell Receptor Repertoire Linked to Anti-PD-1 Therapy Response in Hodgkin Lymphoma Aug 4, 2020 Fluidigm, De Novo Software Ink Distribution Deal Jul 14, 2020 Newly Proposed B Cell Atlas Identifies 12 Unique Subsets May 7, 2020 Fluidigm Q1 Revenues Fall 8 Percent Apr 30, 2020 Washington University, BostonGene Expand Kidney Cancer Research Collaboration Feb 26, 2020 Fluidigm Acquires Cytometry Sample Prep Firm InstruNor for $7.2M Feb 10, 2020 Fluidigm Reports Flat Q4 Revenues Jan 24, 2020 Federal Court Whittles Down Fluidigm Lawsuit Against IonPath Jan 21, 2020 Imaging Mass Cytometry Uncovers Novel Breast Cancer Subgroups Associated With Outcomes Jan 14, 2020 Fluidigm Anticipates Flat Q4 Revenues Nov 5, 2019 Fluidigm Q3 Revenues Fall 9 Percent on Mass Cytometry Weakness Sep 10, 2019 Fluidigm Sues IonPath for Patent Infringement, Interference Aug 1, 2019 Fluidigm Q2 Revenues Grow 7 Percent; Stock Tumbles on Microfluidics Weakness, Soft Guidance May 3, 2019 Fluidigm Q1 Revenues Soar 19 Percent Apr 11, 2019 Fluidigm's New Immune Cell Profiling Assay Could Boost Use of Mass Cytometry Premium Feb 7, 2019 Fluidigm Q4 Revenues Grow 17 Percent on Mass Cytometry Strength Nov 1, 2018 Fluidigm Q3 Revenues Up 17 Percent Oct 9, 2018 10,000 Immunomes Project Establishes Initial Baseline for Healthy Immune System Load More Breaking News MDxHealth Q3 Revenues Grow 23 Percent BioMérieux Q3 Revenues Increase 11 Percent, Firm Raises 2021 Guidance Germline Cancer Risk Genes May Hold Rhabdomyosarcoma Survival Clues, Study Suggests Danaher Q3 Revenues Rise 23 Percent, Beat Wall Street Estimates Horse Genetics Study Reveals Origins of Domestication, Use in Human Culture Rady Children's Team Presents Genomic Medicine Management Tool at ASHG The Scan Guidelines for Ancient DNA Work More than two dozen researchers have developed new ethical guidelines for conducting ancient DNA research, which they present in Nature. And Cleared A UK regulator has cleared former UK Prime Minister David Cameron in concerns he should have registered as a consultant-lobbyist for his work with Illumina, according to the Financial Times. Suit Over Allegations The Boston Globe reports that David Sabatini, who was placed on leave from MIT after allegations of sexual harassment, is suing his accuser, the Whitehead Institute, and the institute's director. Nature Papers on Esophageal Cancer, Origin of Modern Horses, Exome Sequencing of UK Biobank Participants In Nature this week: genetic and environmental influences of esophageal cancer, domestic horse origin traced to Western Eurasian steppes, and more.